Peijia Medical Ltd (9996)
Hong Kong Stock Exchange · Hong Kong · prices in HKD · close of 21 Oct 2026
Key indicators
| Last close | HKD 4.150 |
|---|---|
| 52-week range | 3.730 – 7.370 |
| Return, 1 month / 3 months | −13.6% / −0.7% |
| Return, 1 year / 3 years | −34.4% / −39.7% |
| Trend | Below its 200-day average |
| RSI (14) | 33 |
| Volatility (1 year) | 51.1% |
| Worst drawdown (1 year) | -47.6% |
| Average daily value traded | 3.27M HKD |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Peijia Medical is a medical device company based in Suzhou, China, that develops and makes minimally invasive products for structural heart disease and neurovascular conditions. Its heart valve devices are used to treat aortic valve disease without open surgery, while its neurovascular line includes tools for removing clots in stroke patients and for treating brain aneurysms. The company serves hospitals and specialist physicians in China and other markets through its own sales teams and distribution partners.
The shares are listed on the Hong Kong Stock Exchange in Hong Kong under the code 9996, and the price on this page is in Hong Kong dollars (HKD). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Peijia Medical Ltd (9996) trades on the Hong Kong Stock Exchange in Hong Kong. It last closed at HKD 4.150 on 21 October 2026.
Its price-based Market X-Ray is 48 out of 100 (a weak price profile), ranking 1,395 of 2,611 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 34.4% and over the last three months it fell 0.7%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Hong Kong Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 39 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -22.8% | ||
| From 52-week high | -42.4% | ||
| Momentum | 39 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -0.7% | ||
| 6-month return | -41.5% | ||
| 12-month return, skipping the last month | -24.1% | ||
| Stability (higher is calmer) | 54 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 51.1% | ||
| Worst drawdown, 1 year (smaller is calmer) | -47.6% | ||
| Liquidity | 69 · Fair | Moderate trading activity. | |
| Average daily value traded | 3.27M HKD | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
Returns
| 1 week | −5.6% |
|---|---|
| 1 month | −13.6% |
| 3 months | −0.7% |
| 6 months | −41.5% |
| 1 year | −34.4% |
| 3 years | −39.7% |
| 5 years | – |
Signals
| 50-day / 200-day average | 4.888 / 5.375 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.261 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Hong Kong Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.